Portal de investigação
Can serum endoglin be used to improve the diagnostic performance in prostate cancer?
Autores da FMUP
Participantes de fora da FMUP
- Pina, F
- Ferro, A
- Botelho, F
- Manso, M
- Dias, N
- Figueiredo, G
- Pereira, P
- Dinis, P.
Unidades de investigação
Abstract
Purpose New biomarkers may contribute to avoid unnecessary biopsies resulting from the suboptimal performance of prostate-specific antigen (PSA) testing. This study aimed to assess serum endoglin as a prostate cancer (PCa) diagnostic tool among biopsy candidates. Methods A total of 262 consecutive patients referred for prostate biopsy based on abnormal digital rectal examination and/or elevated total PSA (tPSA) who had serum endoglin assessed by solid-phase enzyme-linked immunosorbent assay were selected. Receiver operating characteristic curves were used to compare the predictive accuracy of different combinations of biomarkers to distinguish between PCa and benign prostatic conditions, and to identify cut-offs that maximize the ability of endoglin to rule out patients for biopsy (highest sensitivities). Results Serum endoglin levels were higher in patients with PCa (median: 7.86 vs. 5.88 pg/mL, P < 0.001). Among patients with baseline tPSA <= 10 ng/mL the area under the curve was 0.69 for endoglin. Approximately one-quarter of the patients had serum endoglin < 4.92 ng/mL (sensitivity: 90.3%; specificity: 32.8%), and the probability of PCa varied from 37.7% before testing to 15.2% among those with low endoglin levels [negative predictive value (NPV) = 84.8%]. When restricting the analyses to patients with free/total PSA ratio > 0.25, the probability of cancer was less than 5% among those with serum endoglin < 6.04 ng/mL (sensitivity: 93.8%; specificity: 56.1%), corresponding to a NPV of 95.8%; this could allow sparing approximately 40% of patients from biopsy. Conclusions Serum endoglin may be useful in clinical practice to distinguish between PCa and non-cancer patients among prostatic biopsy candidates.
Dados da publicação
- ISSN/ISSNe:
- 0724-4983, 1433-8726
- Tipo:
- Article
- Páginas:
- 4135-4142
- Link para outro recurso:
- www.scopus.com
World Journal of Urology Springer Verlag
Documentos
- Não há documentos
Filiações
Keywords
- Prostatic neoplasms; Diagnosis; Endoglin
Proyectos asociados
Reshaping organized cervical cancer screening: strategies to increase the adherence and reduce invitation costs
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2020
Using pooled analyses based on individual participant data for a finer assessment of gastric cancer etiology
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2020
Estudo dos factores de risco cardiovascular numa população adulta da Província do Bengo, Angola
Investigador Principal: José Henrique Dias Pinto de Barros
Estudo Clínico Académico . 2019
RISK AND SURVIVAL OF GASTRIC CANCER RELATES SECOND PRIMARY TUMOURS: A COMPETING RISKS FRAMEWORK
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2019
Citar a publicação
Pina F,Ferro A,Botelho F,Manso M,Dias N,Figueiredo G,Pereira P,Dinis P,Barros H,Lunet N. Can serum endoglin be used to improve the diagnostic performance in prostate cancer?. World J. Urol. 2021. 39. (11):p. 4135-4142. IF:3,661. (2).
